| 27th week of 2022 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20220211665 | PYRROLE AMIDE COMPOUND AND USE THEREOF - A pyrrole amide compound, a pharmaceutical composition thereof and use thereof. The compound or the pharmaceutical composition can be used as a mineralocorticoid receptor antagonist. | 2022-07-07 |
| 20220211666 | COMBINATION TREATMENT OF ARTHRITIC DISEASE - The present invention relates to a composition comprising, separately or together, methotrexate (MTX) and (E)-N-trans-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate (AP1189), or pharmaceutically acceptable derivatives thereof, for use in a method of treating an arthritis disease, such as rheumatoid arthritis. | 2022-07-07 |
| 20220211667 | COMPOSITION FOR THE INTRAPERITONEAL TREATMENT OF SECONDARY BACTERIAL PERITONITIS WITH REDUCTION OF COMPLICATIONS - The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antibiotic agents to treat, pre-emptively treat or prevent infectious peritonitis or intra-abdominal infection and reduce the occurrence of local peritonitis or intra-abdominal abscess resulting therefrom by the intraperitoneal administration of the compositions. | 2022-07-07 |
| 20220211668 | RAPID DISPERSE DOSAGE FORM - A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug. | 2022-07-07 |
| 20220211669 | Methods, Agents, and Compositions for the Treatment of Acute Myeloid Leukemia - A method of treating a subject suffering from a condition characterized by over-expression of Ten-eleven translocation 1 (TET1) is provided, the method including administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the Formula I: | 2022-07-07 |
| 20220211670 | PREVENTING AND TREATING MALARIA - Methods of treating and preventing malaria infection, comprising administering a therapeutically effective amount of cell permeability modulating therapy are provided herein. Among other things, the present disclosure provides parameters that define subjects who are relatively susceptible or resistant to malaria infection. The present disclosure also provides therapeutic strategies for increasing malarial resistance and/or imparting a resistant state on subjects. | 2022-07-07 |
| 20220211671 | INJECTABLE PSYCHOACTIVE ALKALOID COMPOSITION AND PREPARATION THEREOF - The liquid composition includes a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The injectable psychoactive alkaloid composition includes a carrier, an optional tonicity modifier, an optional antioxidant or preservative, an optional pH modifier, and optional further excipients. A process for obtaining an injectable psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients. | 2022-07-07 |
| 20220211672 | METHODS OF TREATING PRURITUS - The present disclosure related to methods of treating pruritus in a subject by topically administering an alpha-2 adrenoreceptor agonist to a subject. | 2022-07-07 |
| 20220211673 | METHODS FOR TREATING AGAINST VIRUSES - A combinatorial method for treating against, or at least inhibiting or suppressing, the proliferation of an internal ribosome entry site utilizing virus (IRES-utilizing virus) in a host in need of treatment involves administering the host a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the IRES-utilizing virus in cells, wherein the compound is represented by the formula: | 2022-07-07 |
| 20220211674 | Thromboxane Receptor Antagonists in AERD/Asthma - The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof. | 2022-07-07 |
| 20220211675 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL - Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions, for example, intraocular pressure, ocular hypertension, and glaucoma. | 2022-07-07 |
| 20220211676 | COMPOSITIONS AND METHODS FOR TREATING MICROBIOTA-RELATED PSYCHOTROPIC CONDITIONS AND DISEASES - In alternative embodiments, the invention provides compositions and methods for treating, ameliorating and preventing various disorders and conditions in manunals, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor, for example, where the microbial or bacterial flora of the bowel manufactures neurotoxins or neurotoxic agents that enter the body through the gastrointestinal (GI) tract, e.g. the colon, and reach the systemic space, e.g., by neural streaming or via the circulation, to reach the central nervous system (CNS), including the brain, the peripheral nervous system (PNS), and other nervous systems. In alternative embodiments, methods and compositions of the invention comprise or comprise use of medications, formulations and pharmaceuticals comprising rifaximin or equivalent active agents that can suppress or eradicate the microbiota super-infection that causes various psychotropic disorders. These compositions have been found to be affective in a broad spectrum of disorders but particularly in the obsessive compulsive disorder group (OCD). | 2022-07-07 |
| 20220211677 | MEDICINE COMBINATIONS AND TREATMENT OF RESTLESS LEG SYNDROME - Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, restless leg syndrome. | 2022-07-07 |
| 20220211678 | USES OF (+)-A-DIHYDROTETRABENAZINE IN METHODS OF TREATING MOVEMENT DISORDER - This invention relates to the use of low doses of (+)-α-dihydrotetrabenazine for the treatment of movement disorders, such as Tourette's syndrome. | 2022-07-07 |
| 20220211679 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS - The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonists for the treatment, amelioration, prevention or delay of progression of fatigue, narcolepsy, excessive daytime sleepiness, nocturnal sleep disturbance, and/or cataplexy. | 2022-07-07 |
| 20220211680 | COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME - Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions. | 2022-07-07 |
| 20220211681 | COMPOSITIONS AND METHODS FOR PREVENTING INFLAMMATORY CONDITIONS - Provided herein are compositions and methods for preventing and/or reducing the risk of inflammatory disease in subject. In particular, provided herein are methods for preventing colorectal cancer in a subject by administering to the subject one or more curcuminoids and vitamin B6. | 2022-07-07 |
| 20220211682 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same. | 2022-07-07 |
| 20220211683 | NOVEL MATERIAL FOR SKIN WOUND CLOSURE AND SCAR PREVENTION - Methods and compositions for preventing or inhibiting the formation of scars are disclosed. The methods and compositions include a TGF-β inhibitor provided in a delayed release composition. | 2022-07-07 |
| 20220211684 | ANTIFUNGAL AGENTS FOR CANDIDA AURIS DECOLONIZATION - Enfumafungin derivative triterpenoid antifungal compounds are used to decolonize fungi from anatomic areas of subjects colonized by fungi. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-β-glucan synthesis and can decolonize | 2022-07-07 |
| 20220211685 | METHODS OF TREATMENT - The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days. | 2022-07-07 |
| 20220211686 | FORMULATIONS OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)M- ETHYL)-2,2-DIFLUOROACETAMIDE - Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formulations and dosage forms for treating, managing, and/or preventing cancer are also provided herein. | 2022-07-07 |
| 20220211687 | USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE - This application is directed to assays, diagnostic methods and treatment methods using arimoclomol for the treatment of Niemann-Pick disease type C (NPC). More specifically, this application is directed to assays, diagnostics methods and treatment methods that target specific clinical subsets of patients with NPC who exhibit at least one missense mutation in at least one allele of an NPC gene. | 2022-07-07 |
| 20220211688 | PHARMACEUTICAL PREPARATION AND METHOD FOR PRODUCING THE SAME - Disclosed is a pharmaceutical preparation in the form of granules having nuclear particles and a coating layer coating the nuclear particles, wherein the nuclear particles are composed of a drug, a first nuclear-particle component, a second nuclear-particle component and a surfactant; the drug is an aniline derivative represented by the following general formula (I): | 2022-07-07 |
| 20220211689 | ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS OF APIXABAN - The present invention relates to an orally disintegrating pharmaceutical dosage forms of apixaban or a pharmaceutically acceptable salt or prodrug thereof. The present invention specifically relates to a stable orally disintegrating pharmaceutical composition comprising apixaban and one or more pharmaceutically acceptable excipients. Further, the present invention relates to an orally disintegrating dosage form comprising apixaban, at least one disintegrating excipient and optionally one or more pharmaceutically acceptable excipients for treatment of disorders associated with Factor Xa. | 2022-07-07 |
| 20220211690 | METHODS FOR TREATING PTEN-MUTANT TUMORS - Methods for assessing the efficacy of dihydroorotate dehydrogenase inhibitors in the treatment of cancer and methods of using such inhibitors to treat PTEN-mutant cancer are provided. | 2022-07-07 |
| 20220211691 | TREATMENT OF DRY EYE DISEASE - The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease. | 2022-07-07 |
| 20220211692 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use - The present invention provides for compounds of Formula (I) | 2022-07-07 |
| 20220211693 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY - A quinoline derivative used for soft tissue sarcoma combination therapy, relating to a use of the quinoline derivative in combination with a second therapeutic drug to treat soft tissue sarcoma, wherein the second therapeutic drug may be a chemotherapy drug, a small molecule targeted anti-tumour drug or an immunotherapy drug. The chemical name of the quinoline derivative compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine. | 2022-07-07 |
| 20220211694 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER - Provided is an application of a compound, 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxy quinolin-7-yl]oxy]methyl]cyclopropylamine, in preparation of a medicament for the treatment of head and neck cancer, and an application of a pharmaceutical composition of the compound combined with a second therapeutic drug in the preparation of a medicament for the treatment of head and neck cancer. The head and neck cancer can also be nasopharyngeal cancer. | 2022-07-07 |
| 20220211695 | MORPHINE-INDUCED RESPIRATORY DEPRESSION: BEHAVIORAL, PHRENIC AND BRAINSTEM RESPIRATORY NEURONAL EVIDENCE - Disclosed is a method for reducing opioid-induced breathing, phrenic and rVRG abnormal activities. The disclosed methods can maintain the desired effects of an opioid while reducing any unwanted breathing problems. | 2022-07-07 |
| 20220211696 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer. | 2022-07-07 |
| 20220211697 | METHODS OF USING PYRUVATE KINASE ACTIVATORS - Described herein are methods for using compounds that activate pyruvate kinase. | 2022-07-07 |
| 20220211698 | ANTI MALARIAL COMPOUNDS - Disclosed herein are compositions and methods to prevent | 2022-07-07 |
| 20220211699 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to a pharmaceutical composition which comprises (a) a combination of (i) trazodone or a salt thereof, and (ii) gabapentin or pregabalin or mirogabalin or a salt thereof or a prodrug thereof, and (b) at least one pharmaceutically acceptable excipient, for use in the treatment of neuropathic pain, wherein said pharmaceutical composition comprises a weight ratio of trazodone:gabapentin or pregabalin or mirogabalin between 1:40 and 1:100, preferably lower than 1:40 and up to 1:100. | 2022-07-07 |
| 20220211700 | Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs - Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for memory dysfunction, Alzheimer's disease, and cognitive decline. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in improving memory, as well as for preventing and treating memory disorders, Alzheimer's disease and cognitive decline. All the above-mentioned methods are computer assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approaches by gender, and by diagnosis, are disclosed. | 2022-07-07 |
| 20220211701 | TREATMENT OF CANCER UTILIZING AN IDENTIFIED ADENOSINE FINGERPRINT - The present disclosure provides methods of treating a cancer in a subject having an established adenosine fingerprint. An established adenosine fingerprint includes assessing the blood concentration of one or more adenosine machinery proteins, assessing the enzymatic activity of one or more adenosine machinery proteins, and/or assessing the tumor expression level of adenosine machinery proteins. The methods disclosed herein include administering to said subjects a therapeutic agent selected from the group consisting of an agent targeting the extracellular production of adenosine, and an agent antagonizing the activation by adenosine of one of its receptors. | 2022-07-07 |
| 20220211702 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION - This document provides methods and materials involved in treating cardiovascular conditions such as calcific aortic valve stenosis. For example, methods and materials for using sGC agonists or a combination of sGC agonists and PDE5A inhibitors to reduce calcification of heart valves and/or vessels or to slow progression of aortic sclerosis to calcific aortic valve stenosis are provided. | 2022-07-07 |
| 20220211703 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | 2022-07-07 |
| 20220211704 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - The compounds depicted below, and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: | 2022-07-07 |
| 20220211705 | PHARMACEUTICAL COMPOSITIONS COMPRISING AFATINIB - The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention. | 2022-07-07 |
| 20220211706 | Methods and Compositions for Treating Cancer - Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor. | 2022-07-07 |
| 20220211707 | TOPICAL FORMULATION FOR A JAK INHIBITOR - This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders. | 2022-07-07 |
| 20220211708 | PHARMACEUTICAL COMBINATION OF PIMOZIDE AND METHOTREXATE AND USE THEREOF - Disclosed are a pharmaceutical combination of pimozide and methotrexate and use thereof. The pharmaceutical combination comprises methotrexate, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of pharmaceutically acceptable salt thereof, and pimozide, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of pharmaceutically acceptable salt thereof. The pharmaceutical combination can be used for the treatment of rheumatoid arthritis. | 2022-07-07 |
| 20220211709 | STABLE, READY TO USE AQUEOUS PHARMACEUTICAL COMPOSITION OF PEMETREXED - The present invention provides a stable, ready to use aqueous parenteral composition comprising Pemetrexed, wherein the composition comprises Pemetrexed disodium, mixture of antioxidants and pharmaceutically acceptable excipients. Further the present invention provides process for preparation of said composition. | 2022-07-07 |
| 20220211710 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH NUCLEOSIDE-METABOLISM MODULATORS - The present invention relates to methods of selecting a subject with cancer for treatment, screening a test molecule for use as a cancer therapeutic, and treating a subject with cancer, as well as compositions for treating cancer. | 2022-07-07 |
| 20220211711 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS - Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART). | 2022-07-07 |
| 20220211712 | TOPICAL FORMULATION FOR A JAK INHIBITOR - This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders. | 2022-07-07 |
| 20220211713 | Compositions Containing Ibrutinib - Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water. | 2022-07-07 |
| 20220211714 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS - The present invention provides compositions and methods for the delivery of antivirals to a cell or subject. | 2022-07-07 |
| 20220211715 | PHARMACEUTICAL COMBINATION - The present invention relates generally to the field of oncology. In particular, the invention relates to a pharmaceutical combination comprising of formula (I) or a pharmaceutically acceptable salt or solvate thereof and an anti-PD-1 antibody or a pharmaceutically acceptable salt or solvate thereof for treating diseases and/or disorders related to the Wnt pathway. | 2022-07-07 |
| 20220211716 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF - The present invention provides prodrugs and methods of use thereof. | 2022-07-07 |
| 20220211717 | TOPICAL TREATMENT OF FUNGAL INFECTIONS OF THE HAIR, SKIN, AND NAILS - This invention discloses methods of preparation and usage of novel pharmaceutical compositions for the topical treatment of resistant fungal infections of the hair, skin, and nails. The compositions targets the fungal cell membrane by inhibiting the biosynthesis of erogosterol, an important structural component of the membrane. The invention consists of combinations of ergosterol biosynthesis inhibitors selected from three different classis, allylamines, azoles, and morpholines. | 2022-07-07 |
| 20220211718 | BCL-2 INHIBITORS FOR USE IN THE TREATMENT OF A BCL-2 MEDIATED CANCER CARRYING THE GLY101VAL MUTATION - The invention relates to a Bcl-2 inhibitor for use in the treatment of a Bcl-2 mediated cancer carrying at least 1, 2, 3, 4, 5 or all of the following mutations: (i) Gly101Val; (ii) Asp103Tyr; (iii) Asp103Val; (iv) Asp103Glu; (v) Arg129Leu and (vi) Ala113Gly; wherein the Bcl-2 inhibitor is N-(4-hydroxyphenyl)-3-{6-[((3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-N-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide (Compound A) or 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-iH-pyrrole-3-carboxamide (Compound B), or a pharmaceutically acceptable salt thereof. | 2022-07-07 |
| 20220211719 | PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA - Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of dyskinesias induced by L-DOPA. The present invention relates to the pharmaceutical field, more particularly to the use of Rho kinase inhibitors for treating or preventing dyskinesias induced by L-DOPA. | 2022-07-07 |
| 20220211720 | DIETARY SUPPLEMENT - A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine, CDP Choline, and optionally, Alpha GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter. | 2022-07-07 |
| 20220211721 | DIETARY SUPPLEMENT - A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine and GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter. | 2022-07-07 |
| 20220211722 | CONTRACEPTIVE COMPOSITIONS WITH REDUCED ADVERSE EFFECTS - The present invention relates to a combined oral contraceptive with a reduced risk for side effects, including a reduced risk for QT interval prolongation, a reduced risk for testosterone decrease and a reduced risk for elevated C-reactive protein levels when compared to other combined oral contraceptives. The estetrol/drospirenone combined oral contraceptive described herein shows favorable pharmacokinetics for the progestogenic component. Use of a specific estrogenic component in the combined oral contraceptive entails multiple benefits over currently available combined oral contraceptives. | 2022-07-07 |
| 20220211723 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX - The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy. | 2022-07-07 |
| 20220211724 | COMPOSITION COMPRISING LIPOIC ACID AND VITAMIN D FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES AND PERIPHERAL NEUROPATHIES - The present invention regards a composition comprising lipoic acid, or an acceptable pharmaceutical or food grade salt thereof or a derivative thereof, and a vitamin D, preferably vitamin D3 and/or vitamin D2, for use in a method for the treatment of neurodegenerative diseases and/or for the treatment of peripheral neuropathies. | 2022-07-07 |
| 20220211725 | Pharmaceutical Composition Comprising Venetoclax - The present subject matter provides amorphous solid dispersions of venetoclax or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising said amorphous solid dispersions. The present subject matter also provides methods for the preparation of said solid dispersions and compositions. The present subject matter further provides pharmaceutical compositions comprising mixture of solid dispersions. | 2022-07-07 |
| 20220211726 | UVEAL MELANOMA TREATMENT - The invention relates to antibiotics inhibiting the 30S ribosomal subunit, such as tigecycline, for use in the treatment of uveal melanoma. | 2022-07-07 |
| 20220211727 | Mito-Magnolol Compounds and Methods of Synthesis and Use Thereof - The present invention provides mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-magnolol compounds in the treatment of cancer, especially anti-cancer therapy or kinase resistant cancers. | 2022-07-07 |
| 20220211728 | ALKYL-TPP COMPOUNDS FOR MITOCHONDRIA TARGETING AND ANTI-CANCER TREATMENTS - Alkyl-triphenylphosphonium compounds having a saturated, linear alkyl chain of about 9 to about 18 carbons may be used as therapeutic agents to treat cancer. Demonstrative compound dodecyl-TPP (d-TPP) dose-dependently inhibits the propagation of breast cancer stem cells and targets the adherent “bulk” of cancer cells, by decreasing MCF-7 cell viability. Further, d-TPP potently inhibits mitochondrial oxygen consumption rate, while simultaneously shifting cell metabolism toward the glycolytic pathway. This shift to a strict metabolic dependency on glycolysis may be used to eradicate the residual glycolytic CSC population, by using additional metabolic stressors. For example, d-TPP may be combined with a glycolytic inhibitor or an OXPHOS inhibitor, through co-administration or sequential administration, to treat cancer and eradicate CSCs. | 2022-07-07 |
| 20220211729 | FORMULATIONS OF CREATINE AND CYCLODEXTRIN EXHIBITING IMPROVD BIOAVAILABILITY - Formulations of creatine, preferably phosphocreatine and most preferably disodium phosphocreatine, combined with cyclodextrin exhibit improved uptake across digestive mucosa, including intestinal, esophageal, and stomach mucosa. In particular, the formulations of the present invention are designed for protection of the cyclodextrin as it comes in contact with gastric juices so as to allow thereafter for unexpectedly improved site-specific intestinal release. | 2022-07-07 |
| 20220211730 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS - The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants. | 2022-07-07 |
| 20220211731 | COMPOSITION FOR PROMOTING GLP-1 SECRETION - It has been expected to develop a better GLP-1 secretagogue component. The present invention provides a composition for promoting GLP-1 secretion that contains emulsified particles comprising an amphiphilic GLP-1 secretagogue component and an emulsifier, wherein the emulsifier is an oil-in-water type emulsifier and the GLP-1 secretagogue component is incorporated in the emulsified particles. | 2022-07-07 |
| 20220211732 | PREBIOTIC COMPOSITIONS - The invention discloses preparations comprising L-rhamnose, and the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the form of either free fatty acids, fatty acid salts having an organic counter ion selected from lysine, arginine, ornithine, choline and mixtures of the same, or mixtures of free fatty acids and omega-3 fatty acid salts having an organic counter ion selected from lysine, arginine, ornithine, choline and use of a preparation as a feed or food supplement or in pharmaceutical compositions. | 2022-07-07 |
| 20220211733 | Compositions and Products for Infectious or Inflammatory Diseases or Conditions - Composition and methods for treating infectious and inflammatory diseases using saccharide based products and therapies. Products can be implemented as a nutritional supplement, a food, a feed, a food additive, a feed additive, a therapeutic product, a rehydration salt, or a rehydration solution. The present disclosure relates generally to the fields of compositions and products containing the compositions, and the use of the compositions or the products for preventing and/or treating infectious or inflammatory diseases or conditions in particular gastrointestinal and respiratory diseases (diarrhea and influenza infections) or inflammatory. | 2022-07-07 |
| 20220211734 | FUCOSYLTRANSFERASE SPECIFIC INHIBITION USING FUCOSE MIMETICS - Provided are compositions and methods for specific fucosyltransferase inhibition for treatment of a variety of diseases. The compositions of the invention comprise a glycomimetic of L-Fucose that selectively inhibits the generation of sialyl Lewis X by FTVI and FTVII but has no effect on the generation of Lewis X by FTIX. | 2022-07-07 |
| 20220211735 | MEDICAMENT AND COMBINATION PRODUCT USED FOR PREVENTING, ALLEVIATING AND/OR TREATING FIBROSIS, AND USE THEREOF - A medicament for preventing, alleviating and/or treating fibrosis comprises one of Carrimycin, Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III; or a combination of two or three of Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III. A combination product for preventing, alleviating and/or treating fibrosis comprises a first drug, an effective component of the first drug comprises one of Carrimycin, Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III; or a combination of two or three of Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III. It also relates to use of the medicine and combination product in preventing, alleviating and/or treating fibrosis. | 2022-07-07 |
| 20220211736 | TREATMENTS OF PROSTATE CANCER - The present invention provides compounds, compositions and methods for the treatment of prostate cancers, preferably, advanced prostate cancers. The subject invention also provides compounds, compositions and methods for preventing/slowing down/reducing the progress and proliferation of prostate cancer cells. The subject invention further provides compounds, compositions and methods for inhibiting DNA repair within cancer cells to slow tumor growth, preferably, by inhibiting BER capacity, including pol β and LIG I. | 2022-07-07 |
| 20220211737 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICHS ATAXIA - The present application provides compositions for treatment of Friedreich's Ataxia (FA). These include, but are not limited to, nucleic acid constructs and recombinant vectors comprising a human frataxin 5′ untranslated region (5′UTR FXN) and a human frataxin (FXN) nucleotide sequence are provided herein. Also provided are methods for treatment of FA. | 2022-07-07 |
| 20220211738 | NANOPARTICLE TO TARGET CANCER - A construct, or a pharmaceutically acceptable salt thereof, comprising:
| 2022-07-07 |
| 20220211739 | OLIGOMERIC NUCLEIC ACID MOLECULE, AND APPLICATION THEREOF IN AN ACUTE INTERMITTENT PORPHYRIA TREATMENT - The present invention relates to compositions of small activating nucleic acid molecules for increasing the expression of HMBS gene and a use thereof. The small activating nucleic acid molecule can be a double-stranded or single-stranded RNA molecule targeting the promoter region of the HMBS gene. The first nucleic acid strand and the second nucleic acid strand each contain a complementary region, and the complementary regions can form a double-stranded nucleic acid structure, which can promote the expression of the HMBS gene. The first nucleic acid strand or the second nucleic acid strand independently have a length of 16 to 35 nucleotides. The 3′ terminus of the two oligonucleotide strands may have an overhang of 0 to 6 nucleotides in length. The small activating nucleic acid molecule for the HMBS gene can be used to up-regulate mRNA and protein expressions of the HMBS gene in a cell and promote enzymatic activity thereof | 2022-07-07 |
| 20220211740 | SIRT1-SARNA COMPOSITIONS AND METHODS OF USE - The disclosure relates to a saRNAs useful in upregulating the expression of the SIRT1 gene and therapeutic compositions comprising the saRNA. Methods of using the saRNA and the therapeutic compositions are also provided. | 2022-07-07 |
| 20220211741 | METHODS FOR THE TREATMENT AND PROGNOSIS OF CANCER - Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. In particular, hepatocellular carcinoma (HCC) has become the most common primary hepatic malignancy. Current therapies are now satisfying and there is therefore an important need for identifying new therapeutic avenues. IL-27 is a cytokine produced in liver microenvironment but its role in the pathogenesis of HCC has never been investigated. The inventors now show that IL-27 exerts anti-proliferative activities in HCC cell lines. However, the inventors show that in patients suffering from HCC that a decreased expression of WSX-1 (i.e. the IL-27 receptor) is associated with a worse prognosis and contributes to the tumor proliferation. The inventors then identified some microRNAs (miR) that are capable of repressing the expression of WSX-1 and show that overexpression of said miR are associated with a worse prognosis in patients. Finally, the inventors demonstrate that antagomirs restore the expression of WSX-1 that can thus restore the tumor cell sensitization to IL-27 properties. Accordingly, the present invention relates to methods for the treatment and prognosis of cancer, in particular hepatocellular carcinoma (HCC). | 2022-07-07 |
| 20220211742 | METHODS AND COMPOSITIONS OF MiR-10 MIMICS AND TARGETS THEREOF - The present invention relates to methods and compositions comprising a miR-10a-5p or miR-10b-5p mimic for treatment of gastrointestinal motility disorders, obesity and diabetes. | 2022-07-07 |
| 20220211743 | ORAL DELIVERY OF OLIGONUCLEOTIDES - One aspect of the present invention relates to an oral formulation for reducing or inhibiting the expression of a target gene in a subject, comprising a) double stranded iRNA agent comprising an antisense strand which is complementary to a target gene; a sense strand which is complementary to said antisense strand; 2′-OMe modifications to more than fifteen, more than twenty, more than twenty-five, or more than thirty nucleotides; and a carbohydrate-based ligand conjugated to at least one strand, optionally via a linker or carrier; and b) a penetration enhancer. Another aspect of the invention relates to a method of gene silencing, comprising orally administering to a subject in need thereof the oral formulation. | 2022-07-07 |
| 20220211744 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) - The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS. | 2022-07-07 |
| 20220211745 | HEALTH BENEFITING COMPOSITIONS OF DAILY NUTRITION AND METHODS OF USE THEREOF - A health benefiting daily nutrition includes protein, the protein having a protein weight. The health benefiting daily nutrition includes fiber, the fiber having a fiber weight. The fiber weight is more than 5 g. A ratio of [the protein weight]:[the fiber weight]=1:0.5-1.5. | 2022-07-07 |
| 20220211746 | SPECIAL HEPARINOID COMPOSITION, WITH REPAIR, PROPHYLACTIC AND ANTI-INFLAMMATORY EFFECTS, APPLIED TO THE LUNGS - The present invention provides a special heparinoid composition, with repair, prophylactic and anti-inflammatory effects, applied to the lungs, which includes at least two glycosaminoglycans, which contain 5˜95 wt % of macromolecular heparin sodium, 3˜40 wt % of low-molecule-weight heparin sodium and 5˜95 wt % of dermatan sulfate are formulated into a solution with a mixture to water ratio of 0.1˜0.6% by weight, and a delivery device is connected to the patient's nose or mouth to deliver to the lungs. The composition of this type of heparinoid has an appropriate dose of disaccharide NH— or O— sulfo and total sulfates, which can make the blood have an anticoagulant effect. During the prophylactic period, more heparin sodium can be added for increasing oxygen and nutrient delivery. At repairing period, more dermatan sulfate with or without chondroitin sulfate can be the main body for better anti-inflammatory repair. | 2022-07-07 |
| 20220211747 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMIDE DERIVATIVES OF HYALURONIC ACID, FOR USE IN THE TREATMENT OF BONE TRAUMAS, IN PARTICULAR OF PATIENTS WITH PROBLEMS OF OSTEOPENIA OR OSTEOPOROSIS - Pharmaceutical compositions are described comprising amide derivatives of hyaluronic acid for use in the treatment of bone mineralization in bone traumas, in particular in patients with problems of osteopenia or osteoporosis. More specifically, these compositions are used in the treatment of bone mineralization in bone fractures, in patients suffering from pathologies characterized by a T-score index lower than −1, preferably lower than −2.5. | 2022-07-07 |
| 20220211748 | NITROGENOUS GAS SUSTAINED RELEASING AGENT AND NITROGENOUS GAS SUSTAINED RELEASER COMPOSED OF THE SAME AS WELL AS NITROGENOUS GAS SUSTAINED RELEASING METHOD, RESPIRATORY EQUIPMENT, PACKAGE, AND SUSTAINED RELEASING APPARATUS USING THE SUSTAINED RELEASER - The invention provides a nitrogenous gas sustained releasing agent that is capable of sustainably releasing off nitrogenous gases in the air at normal temperature and safe to handle and a nitrogenous gas sustained releaser composed of the same as well as a nitrogenous gas sustained releasing method, respiratory equipment, a package and a nitrogenous gas sustained releasing apparatus using said sustained releaser. The nitrogenous gas sustained releasing agent contains a layered double hydroxide having nitrite ions (NO | 2022-07-07 |
| 20220211749 | METHODS FOR PRODUCING ULTRAPURE WATER THAT GENERATES INCREASED CELLULAR PERMEATION - The invention relates to products by processes, product compositions, product formulations and product uses that are all related to reduced ultrapure water cluster sizes in an aqueous composition containing a non-H | 2022-07-07 |
| 20220211750 | COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF - A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells, (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and/or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet. | 2022-07-07 |
| 20220211751 | HIGH MOLECULAR IODINE CONCENTRATION COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, PREPARATION AND USES - Embodiments of high molecular iodine concentration composition and pharmaceutical formulation are disclosed, which may be biostatic persistent, biocidal persistent, and have prolonged biocidal activities against microorganisms for hours after administration of the composition or pharmaceutical formulation. Articles comprising high molecular iodine concentration composition and pharmaceutical formulation, as well as preparation and use of same are also disclosed. | 2022-07-07 |
| 20220211752 | METHIONINE AND CYSTEINE DEPRIVATION DIET AND FORMULATIONS TO INCREASE EFFECTIVENESS OF CANCER THERAPY - Ferroptosis (cell death mediated by iron-dependent lipid peroxide accumulation) results from lipid peroxidation of phospholipids containing polyunsaturated fatty acyl moieties. Glutathione, the key cellular antioxidant capable of inhibiting lipid peroxidation via the activity of the enzyme glutathione peroxidase 4 (GPX-4), is generated directly from the sulfur-containing aminoacid cysteine, and indirectly from methionine via the transsulfuration pathway. Cysteine and methionine deprivation (CMD) in the diet can synergistically increase RSL3-mediated cell death and lipid peroxidation in both murine and human glioma cell lines and in ex-vivo organotypic slice cultures. A cysteine-depleted, methionine-restricted diet can improve survival in an syngeneic orthotopic murine glioma model. This CMD diet leads to profound in-vivo metabolomic, proteomic and lipidomic alterations, leading to improvements in the efficacy of ferroptotic therapies in glioma treatment with a non-invasive dietary modification. | 2022-07-07 |
| 20220211753 | A PHARMACEUTICAL HERBO-MINERAL METALLIC COMPOSITION AND A PROCESS FOR PREPARATION THEREOF - The present disclosure relates to a pharmaceutical herbo-mineral-metallic composition and its process of preparation. The pharmaceutical herbo-mineral-metallic composition comprises Suvarna bhasma, wherein the Suvarna bhasma is obtained by stabilizing Suvarna with fresh juice of the leaves of | 2022-07-07 |
| 20220211754 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MYOSITIS, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT - The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1β, TNF-α, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis. | 2022-07-07 |
| 20220211755 | BIOMATERIALS DERIVED FROM TISSUE EXTRACELLULAR MATRIX - Region-specific extracellular matrix (ECM) biomaterials are provided. Such materials include acellular scaffolds, sponges, solutions, and hydrogels suitable for stem cell culture. | 2022-07-07 |
| 20220211756 | T CELL WHICH EXPRESSES A GAMMA-DELTA T CELL RECEPTOR (TCR) AND A CHIMERIC ANTIGEN RECEPTOR (CAR) - The present invention provides a T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR), wherein the CAR comprises: an antigen binding domain; a transmembrane domain; and a co-stimulatory intracellular signalling domain; wherein the intracellular signalling domain provides a co-stimulatory signal to the T cell following binding of antigen to the antigen binding domain. | 2022-07-07 |
| 20220211757 | ENGINEERED GAMMA DELTA T CELLS AND METHODS OF MAKING AND USING THEREOF - Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered T cells comprising at least one exogenous γδ T cell receptor, for example one that is selected to target a specific disease or pathogen (e.g., cancer or COVID-19). The T cells may be produced from human hematopoietic stem/progenitor cells and are suitable for allogeneic cellular therapy because they do not induce graft-versus-host disease (GvHD) and resist host immune allorejection. Consequently, such cells are suitable for off-the-shelf use in clinical therapy. | 2022-07-07 |
| 20220211758 | AFFINITY MATURATED T CELL RECEPTORS AND USE THEREOF - The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen. | 2022-07-07 |
| 20220211759 | MODULATION OF EXPRESSION OF GENES RELATED TO T CELL EXHAUSTION - The present invention provides methods of preventing, reducing or reversing T cell exhaustion in a patient having a disease. The present invention also provides methods for treating a disease in a patient having the disease. The present invention also provides an engineered T cell, and uses thereof. | 2022-07-07 |
| 20220211760 | NOVEL CANCER ANTIGENS AND METHODS - There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly non small cell lung cancer, especially lung squamous cell carcinoma and melanoma, especially cutaneous melanoma. | 2022-07-07 |
| 20220211761 | GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION - The present disclosure provides genomic safe harbors (GSHs) at which transgenes can be integrated for stable and reliable expression, without disrupting the expression or regulation of the endogenous genes. The present disclosure further provides genetically modified cells comprising a transgene that is integrated within the GSHs disclosed herein. The present disclosure further provides compositions, kits, and formulations comprising genetically modified cells disclosed herein. | 2022-07-07 |
| 20220211762 | PHARMACEUTICAL COMPOSITION FOR TREATING SEPSIS OR SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT - The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1β, TNF-α and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis. | 2022-07-07 |
| 20220211763 | NUTRITIONAL COMPOSITION - The invention relates to a nutritional composition comprising carbohydrates, protein and a fat composition, wherein: (a) the nutritional composition has a total calcium content on dry matter of at least 3.5 g/kg; (b) the protein comprises casein; (c) the nutritional composition has a content of protein-bound calcium of 7.5 mmoles or less per 10 grams of casein; and (d) the ratio NPN to TN is 0.7 or less, with:—NPN meaning non-protein nitrogen in the nutritional composition in grams per 100 grams of nutritional composition (g/100 g); and—TN meaning total nitrogen (TN) in the nutritional composition in g/100 g. The invention further relates to a process for the preparation of the nutritional composition in powder form and to the composition for use in the prevention of gut discomfort and constipation in human subjects, in particular human subjects of 0 to 36 months of age | 2022-07-07 |
| 20220211764 | NEURAL CELL POPULATION, NEURAL CELL-CONTAINING PREPARATION, AND METHOD FOR PRODUCING SAID POPULATION AND PREPARATION - The present disclosure relates to a neural cell population, a neural cell-containing preparation, and a method for producing the population and preparation. More particularly, the present invention relates to a neural cell population derived from intraoral mesenchymal cells, wherein a proportion of normal diploid cells is 80% or more, a preparation containing the neural cell population, and a method for producing the population and the preparation. | 2022-07-07 |
